SLG
JAZZ icon

Stanley-Laman Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stanley-Laman Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,730
Closed -$487K – 289
2016
Q1 		$487K Sell
3,730
-8,403
-69% -$1.05M 0.09% 172
2015
Q4 		$1.71M Buy
12,133
+718
+6% +$99.5K 0.29% 103
2015
Q3 		$1.52M Buy
+11,415
New +$1.97M 0.31% 91

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stanley-Laman Group's JAZZ Position: Q2 2016 in Review

Stanley-Laman Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2016, closing a stake of 3,730 shares — an estimated $487K sold.

Stanley-Laman Group first reported a position in JAZZ in Q3 2015 and held it in 3 quarters. The position peaked at $1.71M in Q4 2015. 366 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

  • Stanley-Laman Group reported no remaining Jazz Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 3,730 Jazz Pharmaceuticals shares in Q2 2016, an estimated $487K.
  • Stanley-Laman Group first reported a position in Jazz Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Stanley-Laman Group's Jazz Pharmaceuticals position peaked at $1.71M in Q4 2015.
  • 366 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.